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The study was designed in collaboration between the CDC and the Principal Investigators at each site. Data 
were electronically transferred to a central database, where they were analyzed by the investigators. All the 
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authors vouch for the accuracy and completeness of the data. The manuscript was drafted by the first author 
and last author, with input from all of the other investigators listed as authors.  
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METHODS 
Study design and methods 
The Centers for Disease Control and Prevention (CDC) initiated the New Vaccine Surveillance Network 
(NVSN), a prospective, population-based inpatient and outpatient surveillance system enrolling children <5 
years old with ARI or fever beginning in 2000 in Nashville and Rochester, and in 2003 in Cincinnati1-4. The 
NVSN surveillance study ended in 2009. Inpatient specimens collected in Cincinnati between 2005-2008 
seasons were excluded due to protocol deviations but outpatient samples were retained; inpatient and 
outpatient samples from Rochester for the 2008-2009 year were not included due to inadequate sample 
amounts. Nasal and throat swabs were obtained for viral detection by the research team. 
 
Children < 5 years old with ARI or fever were enrolled within 48 hours of hospital admission from Sunday 
through Thursday; outpatient surveillance was conducted concurrently. Outpatients were enrolled from 1 to 4 
urban and suburban pediatric practices either 1 or 2 days per week. ED subjects were enrolled at Nashville 
and Rochester during daytime and nighttime shifts 3 or 4 days per week; and at Cincinnati every fourth day. 
 
Each subject was enrolled and tested for HMPV in only one clinical setting. If subjects were enrolled in the 
clinic or ED but later were admitted on non-surveillance days (and thus not enrolled as inpatients), they were 
kept as clinic or ED visits.  If children were enrolled in the clinic or ED but were admitted within 6 days later on 
a surveillance day, they were re-categorized as inpatients. If children sought care in the ED on a surveillance 
day within 4 days of the preceding clinic visit, they were considered ED patients.  
 
There were 283 children who were enrolled more than once during the course of the study; of these, 244 
children tested negative and 39 children tested positive for HMPV.  No child tested HMPV+ more than once. 
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RESULTS 
 
Other viruses tested among inpatients 
 
The primary NVSN study was funded for influenza surveillance in pediatric populations, and thus other 
pathogens were not systematically tested. However, other viruses were tested in some years and some 
settings, and in some cases, population-based rates of hospitalization calculated. Influenza inpatient and 
outpatient rates were published for NVSN study years 2000-20043. Additional testing and population-based 
rate estimates have been performed for RSV inpatient and outpatient study years 2000-20041; parainfluenza 
viruses (PIV) inpatient study years 2000-20044; coronaviruses (HCoV) inpatient study years 2001-20035; and 
human rhinovirus (HRV) inpatient study years 2001-20036. Thus, not all years tested for different viruses 
overlap between these different substudies. Supplemental Table 1 shows the estimated population-based 
rates of hospitalization by age group for each of these viruses. For clarity of the Table, 95% confidence 
intervals are not shown.  
 
Two additional NVSN studies reported HCoV inpatient and healthy controls in study years 2003-20057 and 
HRV inpatient and healthy controls in study years 2003-20058. These studies did not calculate population-
based rates of hospitalization, but reported the rate of viral detection in the two groups. HCoV was detected in 
113 (7.6%) of 1481 hospitalized children and 53 (7.1%) of 742 controls, and thus the prevalence of HCoV was 
not significantly higher among hospitalized children than controls. Overall, HRV was detected in 226 (14.9%) of 
hospitalized children <5 years and 99 (12.5%) of control children <5 years and thus not significantly different. 
However, the HRV-A detection rate among children ≥24 months was 8.1% in hospitalized and 2.2% in control 
children (p=0.009), and the HRV-C detection rate in children ≥6 months were 8.2% and 3.9%, respectively 
(p=0.002). Therefore, while HCoV and HRV are respiratory pathogens, these viruses are also frequently 
detected in asymptomatic children, complicating the attribution of causation in some cases9. 
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Supplemental Table 1. Rates of hospitalization for children <5 years old (per 1000 children) associated with all viruses tested during different years 
of the NVSN study. For clarity, 95% confidence intervals are not shown. 
 
 
Incidence of hospitalization per 1000 children <5 years old 
 
Study years 2003-2009 2000-2004 2000-2004 2000-2004 2000-2004 2000-2004 2001-2003 2001-2003 
Age group 
(months) 
HMPV RSV Influenza# PIV1 PIV2 PIV3 HCoV* HRV 
<6 3.0 16.9 4.5 1.0 0.4 1.6 1.0 7.2 
6-11 2.0 5.1 
0.9 
0.6 0.2 1.0 
0.4 2.6 
12-23 1.2 2.7 0.6 0.2 0.7 
24-59 0.5 0.4 0.3 0.2 0.1 0.2 0 1.2 
0-59 1.0 3.0 0.9 0.4 0.1 0.5 2.3 2.2 
Reference This study 1 3 4 5 6 
 
# Includes influenza A and B 
* Includes HCoV HKU1, NL63, OC43, 229E 
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Other viruses tested among outpatients 
Other viruses were tested in some years for the outpatient settings and population-based visit rates calculated. 
These include RSV inpatient and outpatient study years 2000-20041; and influenza inpatient and outpatient 
rates for NVSN study years 2000-20043. Supplemental Table 2 shows the estimated population-based rates of 
clinic and ED visits by age group for each of these viruses. For clarity, 95% confidence intervals are not shown. 
Supplemental Table 2. Rates of outpatient visits associated with viruses tested during different years of the 
NVSN study. 
 Rate of outpatient visits per 1000 children <5 years old 
Study years 2003-2009 2002-2004 2002-2003 2003-2004 
Pediatric clinics     
Age group 
(months) 
HMPV RSV Influenza# 
<6 58 132 28 59 
6-11 102 177 
52 125 
12-23 75 66 
24-59 39 57 53 88 
0-59 55 80 50 95 
 
Emergency department     
<6 16 55 0 23 
6-11 29 57 
8 39 
12-23 17 32 
24-59 9 13 7 23 
0-59 13 28 6 27 
     
Reference This study 1 3 
# Includes influenza A and B  
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Other viruses detected in children with HMPV infection 
 
Other viruses were detected in 21 (10%) of HMPV-positive hospitalized children and 27 (6%) of HMPV-positive 
outpatient children. The severity of illness was not different in children with more than one virus, but the 
numbers were small (not shown).  
 
Supplemental Table 3. Co-detection of other viruses in patients with HMPV. 
 
HMPV+ RSV+ Influenza+ PIV+ 
Number (%) 
Inpatient    
21 (10) 13 (6) 6 (3) 2 (1) 
    
Outpatient    
27 (6) 14 (4) 11 (2) 2 (1) 
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Supplemental Table 4. Discharge diagnoses for children with and those without HMPV infection. 
Variable Inpatients Outpatients 
 
HMPV positive 
(n=200) 
HMPV negative 
(n=3290) 
HMPV positive 
(n=446) 
HMPV negative 
(n=5812) 
Discharge diagnosis     
Pneumonia 99/200 (50) 731/3290 (22) 39/446 (9) 259/5812 (4) 
Bronchiolitis 44/200 (22) 987/3290 (30) 46/446 (10) 544/5812 (9) 
Asthma 29/200 (14) 419/3290 (13) 62/446 (14) 530/5812 (9) 
Viral illness 11/200 (6) 391/3290 (12) 152/446 (34) 2058/5812 (35) 
Fever 8/200 (4) 294/3290 (9) 19/446 (4) 314/5812 (5) 
Influenza 0/200 (0) 59/3290 (2) 4/446 (1) 77/5812 (1) 
Seizure 1/200 (0) 52/3290 (2) 2/446 (0) 15/5812 (0) 
Bacteremia/septicemia 2/200 (1) 39/3290 (1) 0/446 (0) 3/5812 (0) 
Pharyngitis 0/200 (0) 13/3290 (0) 13/446 (3) 206/5812 (4) 
Sinusitis 1/200 (0) 4/3290 (0) 5/446 (1) 74/5812 (1) 
 
 
Diagnosis at discharge was reported on the basis of up to 10 discharge diagnoses, ordered by 
pneumonia, bronchiolitis, asthma, viral illness (including nonspecific viral illness, croup, 
respiratory syncytial virus infection, and upper respiratory infection), fever, influenza, seizure, 
bacteremia or septicemia, pharyngitis, and sinusitis. 
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